Abstract
Sleep disorders have been shown to increase the risk of dementia. This particular aspect may affect the cognition of the patient, leading to behavioral disorders and depression. In early symptomatic Alzheimer’s Disease (AD), Default Mode Network (DMN) disruption occurs and progresses along with the course of the disease. This review mainly focuses on the leading causes of AD along with management of conditions like insomnia, obstructive sleep apnea, night-time sleep duration, Circadian Rhythm Disorder (CRD), neuroendocrine alternation, and impaired sleep to prevent the use of drugs that can cause complications, especially falls or additional cognitive deficits. Moreover, this study highlights the identification of molecular mechanisms like the effect of impaired sleep on amyloid β (Aβ) and tau dynamics, impaired proteostasis, along with appropriate measures to treat few contributing factors that lead to insomnia in AD or Mild Cognitive Impairment (MCI).
Keywords: Alzheimer's disease, dementia, impaired sleep, insomnia, cognitive impairment, sleep disturbance.
Graphical Abstract
CNS & Neurological Disorders - Drug Targets
Title:Modifiable Risk Factors Associated with Alzheimer’s Disease with Special Reference to Sleep Disturbance
Volume: 20 Issue: 7
Author(s): Pallavi Singh Chauhan, Meerambika Mishra, Bhupendra Koul, Mayank Sharma and Dhananjay Yadav*
Affiliation:
- Department of Medical Biotechnology, Yeungnam University, Gyeongsan 38541,South Korea
Keywords: Alzheimer's disease, dementia, impaired sleep, insomnia, cognitive impairment, sleep disturbance.
Abstract: Sleep disorders have been shown to increase the risk of dementia. This particular aspect may affect the cognition of the patient, leading to behavioral disorders and depression. In early symptomatic Alzheimer’s Disease (AD), Default Mode Network (DMN) disruption occurs and progresses along with the course of the disease. This review mainly focuses on the leading causes of AD along with management of conditions like insomnia, obstructive sleep apnea, night-time sleep duration, Circadian Rhythm Disorder (CRD), neuroendocrine alternation, and impaired sleep to prevent the use of drugs that can cause complications, especially falls or additional cognitive deficits. Moreover, this study highlights the identification of molecular mechanisms like the effect of impaired sleep on amyloid β (Aβ) and tau dynamics, impaired proteostasis, along with appropriate measures to treat few contributing factors that lead to insomnia in AD or Mild Cognitive Impairment (MCI).
Export Options
About this article
Cite this article as:
Chauhan Singh Pallavi , Mishra Meerambika , Koul Bhupendra , Sharma Mayank and Yadav Dhananjay *, Modifiable Risk Factors Associated with Alzheimer’s Disease with Special Reference to Sleep Disturbance, CNS & Neurological Disorders - Drug Targets 2021; 20 (7) . https://dx.doi.org/10.2174/1871527320666210319111852
DOI https://dx.doi.org/10.2174/1871527320666210319111852 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Induction of Cytochrome P450 3A4 and P-Glycoprotein by the Isoxazolyl- Penicillin Antibiotic Flucloxacillin
Current Drug Metabolism Prescription Patterns and Compliance with Antimicrobial Stewardship Team Recommendations Among Physicians in a Private Hospital in United Arab Emirates
New Emirates Medical Journal Bacteriophages and Phage-Derived Proteins – Application Approaches
Current Medicinal Chemistry Replicative Oncolytic Herpes Simplex Viruses in Combination Cancer Therapies
Current Gene Therapy Lung Cancer Chemotherapy, New Treatment and Related Patents
Recent Patents on Anti-Cancer Drug Discovery The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
Current Medicinal Chemistry Recent Progress in Cerebrovascular Gene Therapy
Current Neurovascular Research Coumarins as Inhibitors of HIV Reverse Transcriptase
Current HIV Research Activin-A: A New Piece in the Puzzle of Tolerance in Asthma
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Pharmacodynamics and Pharmacokinetics of Antifungals for Treatment of Invasive Aspergillosis
Current Pharmaceutical Design Editorial [ Hot Topic:Stroke Bugs: Current and Emerging Concepts Relevant to Infection in Cerebrovascular Disease (Guest Editors: Hedley CA Emsley and Angel Chamorro)]
Infectious Disorders - Drug Targets Update on the Therapy of Behçets Disease
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Molecular Genetics of Migraine: Toward the Identification of Responsible Genes
Current Genomics Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy
Current Drug Discovery Technologies Current Directions in Non-Invasive Low Intensity Electric Brain Stimulation for Depressive Disorder
CNS & Neurological Disorders - Drug Targets A Review of Systemic Vasodilators in Low Cardiac Output Syndrome Following Pediatric Cardiac Surgery
Current Vascular Pharmacology Antibiotic Properties and Applications of Lactoferrin
Current Pharmaceutical Design Immunopathology of Brucella Infection
Recent Patents on Anti-Infective Drug Discovery Recent Advances and Challenges in Steroid Metabolomics for Biomarker Discovery
Current Medicinal Chemistry A New Comprehensive Index for Evaluating the Quality of Infant Formula under the Framework of Chinese Food Standards
Current Bioinformatics